查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930119

全球子宫颈癌疫苗市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考量因素以及未来预测（2026-2034）

Cervical Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

子宫颈癌疫苗市场成长因素

近年来，受疾病盛行率上升和全球疫苗接种计画扩大的推动，全球子宫颈癌疫苗市场呈现强劲成长势头。截至2025年，该市场价值达123.6亿美元。在公众意识提高和疫苗接种覆盖范围扩大的推动下，预计该市场将在2026年达到141.6亿美元，并在2034年达到541亿美元，预测期内复合年增长率（CAGR）为18.70%。北美地区在2025年引领全球市场，占34.50%的市占率。这主要得益于该地区较高的疫苗接种率和完善的医疗保健基础设施。

子宫颈癌是全球女性最常见的癌症之一，主要由持续感染高危险型人类乳突病毒 (HPV) 引起。由于免疫反应减弱，感染 HIV 的女性罹患子宫颈癌的风险显着较高。 HPV 是一种性传染病，是导致晚期子宫颈癌的主要原因，因此推动了疫苗接种的需求。

市场动态

市场驱动因素

子宫颈癌发生率的上升是市场成长的主要驱动因素。 HPV 感染率的上升、资源匮乏地区意识不足、社会经济差距、吸烟、人口老化和免疫功能减弱等因素都加剧了疾病负担。根据世界卫生组织 (WHO) 预测，2022 年全球将新增约 66 万例子宫颈癌病例，导致约 35 万人死亡，凸显了有效疫苗接种计画的迫切性。 疾病盛行率的不断上升持续推动着全球子宫颈癌疫苗的普及。

市场限制因子

儘管成长前景强劲，但疫苗犹豫和错误讯息对市场扩张构成挑战。文化偏见、对疫苗安全性的误解以及诸如青少年接种疫苗会导致不孕等错误观念，导致一些地区的疫苗接种率偏低。根据Ecancer Medical Science于2024年8月发布的报告，迷信和错误讯息仍然是子宫颈癌疫苗普及的主要挑战，尤其是在较保守的社会中。

市场机会

不断扩大的公私合作关係正在创造新的成长机会。各国政府、非政府组织和製药公司正在加强合作，透过全球疫苗免疫联盟（Gavi）、世界卫生组织（WHO）和国际药品采购机制（Unitaid）等机构主导的倡议，提高服务不足地区的HPV疫苗接种率。 2024年12月，Unitaid和Gavi携手合作，旨在改善子宫颈癌疫苗的可及性，支持提高公众意识的项目，并降低疫苗的可负担性。

市场挑战

低收入和中等收入国家（LMICs）医疗基础设施的匮乏构成了重大挑战。冷链维护、电力供应不稳定以及医疗设施有限等问题阻碍了疫苗的分发。根据 "临床妇产科杂誌" 报导，子宫颈癌仍然是低收入和中等收入国家女性最常见的癌症。此外，HPV DNA筛检的高成本和基础设施要求进一步限制了这些地区的市场成长。

市场趋势

影响市场的显着趋势是单剂HPV疫苗的广泛应用。传统的两剂或三剂接种方案往往导致依从性低，尤其是在资源匮乏的地区。单剂疫苗的有效性已得到临床证实，简化了疫苗接种方案并提高了覆盖率。 2022年4月，世界卫生组织免疫策略咨询专家小组（SAGE）确认，单剂疫苗可提供HPV的有效保护。

其他值得关注的趋势包括旨在透过男女接种疫苗来降低HPV整体感染率的性别中立疫苗策略，以及国产、价格合理的疫苗的兴起。 2023年1月，印度血清研究所推出了该国首款国产HPV疫苗CERVAVAC，显着提高了疫苗的可及性和可负担性。

市场区隔分析

依疫苗类型划分，市场分为预防性疫苗和治疗性疫苗。截至2024年，预防性疫苗（目前唯一获准用于预防子宫颈癌的疫苗）占市场主导地位。根据世界卫生组织2024年7月报告，治疗性疫苗预计将实现最快成长，目前有超过20种候选疫苗正在进行临床开发。

依技术划分，分子疫苗因其安全性、有效性和易于生产而占市场主导地位。这些疫苗利用病毒样颗粒（VLP）诱发强烈的免疫反应。载体疫苗也因其持久的免疫力而占了相当大的占有率。

依分销管道划分，医院药房在2024年占主导地位，这主要得益于患者接种疫苗的就诊量巨大。政府和机构供应管道也占了相当大的占有率，这主要归功于大规模的公共疫苗接种计划。

区域展望

北美市场领先，预计在2026年将创造48.5亿美元的收入，这主要得益于高疾病流行率和强有力的政府举措。欧洲凭藉其医疗保健系统和集中化的疫苗采购，占了第二大市场。亚太地区成为成长最快的地区，这主要得益于子宫颈癌的高发生率以及印度 "终结子宫颈癌使命" 等措施。 由于人们意识的提高和疫苗接种计划的扩大，预计拉丁美洲和中东及非洲地区将出现稳定增长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家和地区子宫颈癌盛行率（2025 年）
  • 主要国家及地区监理概况
  • 主要公司产品线分析
  • 主要产业趋势：併购、业务合作
  • 主要公司新产品发布

第五章 全球子宫颈癌疫苗市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依疫苗类型划分
    • 预防性疫苗
    • 治疗性疫苗
  • 市场分析、洞察与预测：依技术划分
    • 分子生物学疫苗
    • 载体疫苗
    • 其他
  • 市场分析、洞察与预测：依通路划分
    • 医院
    • 政府及机构供应
    • 其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东及非洲

第六章 北美子宫颈癌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲子宫颈癌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区子宫颈癌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲子宫颈癌疫苗市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

    第十章：中东与非洲子宫颈癌疫苗市场分析：洞察与预测（2021-2034）

    • 依国家划分
      • 海湾合作委员会（GCC）国家/地区
      • 南非
      • 中东和非洲其他地区

    第十一章 竞争分析

    • 全球市占率分析（2025 年）
    • 公司简介
    • GSK plc.
    • Merck &Co., Inc.
    • Serum Institute of India Pvt. Ltd.
    • THERAVECTYS
    • ViciniVax
    • Walvax Biotechnology Co., Ltd.
    • Xiamen Innovax Biotech CO., LTD.
Product Code: FBI113609

Growth Factors of cervical cancer vaccines Market

The global cervical cancer vaccines market demonstrated strong growth momentum in recent years, driven by increasing disease prevalence and expanding vaccination programs worldwide. In 2025, the market was valued at USD 12.36 billion. With rising awareness and extended immunization coverage, the market is projected to grow to USD 14.16 billion in 2026 and further reach USD 54.1 billion by 2034, registering a CAGR of 18.70% during the forecast period. North America dominated the global market in 2025, accounting for 34.50% market share, supported by high vaccine adoption rates and strong healthcare infrastructure.

Cervical cancer remains one of the most common cancers among women globally and is primarily caused by persistent infection with high-risk human papillomavirus (HPV) strains. Women living with HIV are at significantly higher risk of developing cervical cancer due to weakened immune responses. HPV, a sexually transmitted infection, is the major etiological factor behind progressive cervical cancer cases, increasing the demand for preventive vaccination.

Market Dynamics

Market Drivers

The rising prevalence of cervical cancer is a key driver of market growth. Factors such as increasing HPV incidence, lack of awareness in low-resource settings, socio-economic inequalities, smoking, aging populations, and compromised immune systems contribute to the growing disease burden. According to the World Health Organization (WHO), approximately 660,000 new cervical cancer cases were reported globally in 2022, resulting in around 350,000 deaths, highlighting the urgent need for effective vaccination programs. This growing disease prevalence continues to increase the adoption of cervical cancer vaccines worldwide.

Market Restraints

Despite strong growth prospects, vaccine hesitancy and misinformation present challenges to market expansion. Cultural stigma, misconceptions regarding vaccine safety, and false beliefs-such as infertility risks associated with adolescent vaccination-reduce uptake in several regions. As reported by Ecancer Medical Science in August 2024, myths and misinformation remain major barriers to cervical cancer vaccine adoption, particularly in conservative societies.

Market Opportunities

The expansion of public-private partnerships is creating new growth opportunities. Governments, NGOs, and pharmaceutical companies are increasingly collaborating to improve HPV vaccination coverage in underserved regions through initiatives led by organizations such as Gavi, WHO, and Unitaid. In December 2024, Unitaid and Gavi partnered to enhance access to cervical cancer preventive vaccines, supporting awareness programs and improving vaccine affordability.

Market Challenges

Limited healthcare infrastructure in low- and middle-income countries (LMICs) poses a significant challenge. Issues such as cold-chain maintenance, unreliable electricity supply, and limited access to healthcare facilities restrict vaccine distribution. According to the Journal of Clinical Obstetrics and Gynecology, cervical cancer remains the most common cancer affecting women in LMICs. Additionally, the high cost of HPV DNA screening and infrastructure requirements further constrain market growth in these regions.

Market Trends

A prominent trend shaping the market is the shift toward single-dose HPV vaccination. Traditional two- or three-dose schedules often result in lower compliance, particularly in resource-limited settings. Clinical evidence now supports the effectiveness of a single dose, simplifying immunization programs and improving coverage. In April 2022, WHO's Strategic Advisory Group of Experts on Immunization (SAGE) confirmed that a single dose provides solid protection against HPV.

Other notable trends include gender-neutral vaccination strategies, which aim to reduce overall HPV transmission by vaccinating both boys and girls, and the rise of indigenous and affordable vaccines. In January 2023, the Serum Institute of India launched CERVAVAC, India's first domestically developed HPV vaccine, significantly improving affordability and access.

Segmentation Analysis

By vaccine type, the market is divided into preventive and therapeutic vaccines. Preventive vaccines dominated the market in 2024, as they are currently the only approved option for cervical cancer prevention. Therapeutic vaccines are expected to witness the fastest growth due to more than 20 candidates in clinical development, as reported by WHO in July 2024.

By technology, molecular-based vaccines dominated the market due to their safety, efficacy, and ease of manufacturing. These vaccines utilize virus-like particles (VLPs) to generate strong immune responses. Vector-based vaccines also held a significant share due to their long-lasting immunity.

By distribution channel, hospital pharmacies dominated in 2024, supported by high patient visits for vaccination. Government and organization supply channels also held a substantial share due to large-scale public immunization programs.

Regional Outlook

North America led the market, generating USD 4.85 billion in revenue in 2026, driven by high disease prevalence and strong government initiatives. Europe followed with significant market share due to universal healthcare systems and centralized vaccine procurement. Asia Pacific emerged as the fastest-growing region, supported by high cervical cancer incidence and initiatives such as India's "Cervical Cancer Mukt Bharat" mission. Latin America and the Middle East & Africa are expected to witness steady growth due to rising awareness and expanding vaccination programs.

Competitive Landscape

The market is dominated by GSK plc., Merck & Co., Inc., and Serum Institute of India Pvt. Ltd. GSK's Cervarix and Merck's Gardasil remain widely adopted globally. Companies continue to invest heavily in R&D and therapeutic vaccine development to strengthen their market presence.

Conclusion

The global cervical cancer vaccines market is witnessing robust expansion, driven by the rising burden of cervical cancer, increasing HPV prevalence, and expanding vaccination coverage across developed and emerging regions. Valued at USD 12.36 billion in 2025, the market is projected to reach USD 14.16 billion in 2026 and further grow to USD 54.1 billion by 2034, reflecting strong long-term growth momentum. Preventive vaccines continue to dominate due to their proven efficacy and regulatory approvals, while therapeutic vaccines are gaining traction with a growing clinical pipeline. Technological advancements, particularly molecular-based vaccine platforms, along with trends such as single-dose vaccination, gender-neutral immunization, and the development of affordable indigenous vaccines, are reshaping market dynamics. Although challenges such as vaccine hesitancy and limited healthcare infrastructure in low- and middle-income countries persist, increasing public-private partnerships, government initiatives, and sustained R&D investments by key players are expected to support market expansion throughout the forecast period.

Segmentation By Vaccine Type

  • Preventive Vaccine
  • Therapeutic Vaccine

By Technology

  • Molecular-based
  • Vector-based
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Government & Organization Supply
  • Others

By Region

  • North America (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • U.S.
    • Canada
  • Europe (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cervical Cancer, by Key Countries/Region, 2025
  • 4.2. Overview of Regol atory Scenario, by Key Countries/Regions
  • 4.3. Pipeline Analysis, Key Players
  • 4.4. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.5. New Product Launches, By Key Players

5. Global Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 5.1.1. Preventive Vaccine
    • 5.1.2. Therapeutic Vaccine
  • 5.2. Market Analysis, Insights and Forecast - By Technology
    • 5.2.1. Molecol ar-based
    • 5.2.2. Vector-based
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospitals
    • 5.3.2. Government & Organization Supply
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 6.1.1. Preventive Vaccine
    • 6.1.2. Therapeutic Vaccine
  • 6.2. Market Analysis, Insights and Forecast - By Technology
    • 6.2.1. Molecol ar-based
    • 6.2.2. Vector-based
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospitals
    • 6.3.2. Government & Organization Supply
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 7.1.1. Preventive Vaccine
    • 7.1.2. Therapeutic Vaccine
  • 7.2. Market Analysis, Insights and Forecast - By Technology
    • 7.2.1. Molecol ar-based
    • 7.2.2. Vector-based
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospitals
    • 7.3.2. Government & Organization Supply
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 8.1.1. Preventive Vaccine
    • 8.1.2. Therapeutic Vaccine
  • 8.2. Market Analysis, Insights and Forecast - By Technology
    • 8.2.1. Molecol ar-based
    • 8.2.2. Vector-based
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospitals
    • 8.3.2. Government & Organization Supply
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 9.1.1. Preventive Vaccine
    • 9.1.2. Therapeutic Vaccine
  • 9.2. Market Analysis, Insights and Forecast - By Technology
    • 9.2.1. Molecol ar-based
    • 9.2.2. Vector-based
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospitals
    • 9.3.2. Government & Organization Supply
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 10.1.1. Preventive Vaccine
    • 10.1.2. Therapeutic Vaccine
  • 10.2. Market Analysis, Insights and Forecast - By Technology
    • 10.2.1. Molecol ar-based
    • 10.2.2. Vector-based
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospitals
    • 10.3.2. Government & Organization Supply
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT,Etc.
    • 11.2.2. Merck & Co., Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT,Etc.
    • 11.2.3. Serum Institute of India Pvt. Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT,Etc.
    • 11.2.4. THERAVECTYS
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT,Etc.
    • 11.2.5. ViciniVax
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT,Etc.
    • 11.2.6. Walvax Biotechnology Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. Financials (Based on Availability)
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. SWOT,Etc.
    • 11.2.7. Xiamen Innovax Biotech CO., LTD.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. Financials (Based on Availability)
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. SWOT,Etc.

List of Tables

  • Table 1: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2021-2034
  • Table 2: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 3: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2021-2034
  • Table 6: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 7: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2021-2034
  • Table 10: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 11: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2021-2034
  • Table 14: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 15: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2021-2034
  • Table 18: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 19: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2021-2034
  • Table 22: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 23: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cervical Cancer Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2025 & 2034
  • Figure 3: Global Cervical Cancer Vaccines Market Value Share (%), by Technology, 2025 & 2034
  • Figure 4: Global Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Cervical Cancer Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2025 & 2034
  • Figure 7: North America Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2025
  • Figure 8: North America Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 9: North America Cervical Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 10: North America Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Cervical Cancer Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Cervical Cancer Vaccines Market Value Share (%), By Country, 2025
  • Figure 14: Europe Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2025 & 2034
  • Figure 15: Europe Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2025
  • Figure 16: Europe Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 17: Europe Cervical Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 18: Europe Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2025 & 2034
  • Figure 23: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2025
  • Figure 24: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 25: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 26: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2025 & 2034
  • Figure 31: Latin America Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2025
  • Figure 32: Latin America Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 33: Latin America Cervical Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 34: Latin America Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2025 & 2034
  • Figure 39: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2025
  • Figure 40: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 41: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 42: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Cervical Cancer Vaccines Market Share (%), By Company, 2025